Bio-Techne Corp (TECH) To Go Ex-Dividend on November 17th

Bio-Techne Corp (NASDAQ:TECH) declared a quarterly dividend on Wednesday, November 5th. Investors of record on Monday, November 17th will be given a dividend of 0.08 per share by the biotechnology company on Friday, November 28th. This represents a c) dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Monday, November 17th.

Bio-Techne has a dividend payout ratio of 15.4% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Bio-Techne to earn $1.97 per share next year, which means the company should continue to be able to cover its $0.32 annual dividend with an expected future payout ratio of 16.2%.

Bio-Techne Trading Down 2.9%

Shares of Bio-Techne stock opened at $58.18 on Friday. The stock has a 50 day moving average of $57.57 and a 200 day moving average of $53.70. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.38 and a current ratio of 3.46. The firm has a market capitalization of $9.06 billion, a price-to-earnings ratio of 126.48, a PEG ratio of 3.63 and a beta of 1.51. Bio-Techne has a fifty-two week low of $46.01 and a fifty-two week high of $79.28.

Bio-Techne (NASDAQ:TECH) last posted its earnings results on Wednesday, November 5th. The biotechnology company reported $0.42 EPS for the quarter, meeting analysts’ consensus estimates of $0.42. The company had revenue of $286.56 million for the quarter, compared to the consensus estimate of $292.02 million. Bio-Techne had a return on equity of 13.43% and a net margin of 6.02%.The company’s revenue for the quarter was down 1.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.42 earnings per share. As a group, research analysts predict that Bio-Techne will post 1.67 earnings per share for the current year.

About Bio-Techne

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.